Company Overview and News

 
Canadian Life Companies Split Corp. Extends Termination Date and Increases Preferred Share Rate

2018-09-26 globenewswire
TORONTO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Canadian Life Companies Split Corp (the "Company") is pleased to announce it has extended the termination date of the Company a further six year period from December 1, 2018 to December 1, 2024.
SLF GWO SLF MFC 0945 GWLOF MFC SLFYF GWLIF SLF

 
Life & Banc Split Corp. Announces Distribution Rates

2018-09-25 globenewswire
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- (TSX: LBS, LBS.PR.A) Life & Banc Split Corp. (the “Fund”) announces that the distribution rate for the Preferred Shares for the 5 year term from November 30, 2018 to October 30, 2023 will be $0.545 per annum (5.45% on the original issue price of $10) payable quarterly. The Preferred Share distribution rate is based on current market rates for preferred shares with similar terms.
SLF TD LBS GWO TD TNTTF TXCX SLF MFC 0945 GWLOF MFC SLFYF GWLIF SLF

14
North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-09-19 globenewswire
TORONTO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable October 10, 2018 to shareholders on record as at September 28, 2018.
CIFAF GLSSP GWO JBK TFG MFC 0945 CGBBW CIX SLFYF GWLIF SLF WFCNP FFN NAF.UN SLF TD GS TD WFC TNTTF C GSC GSJ SLF GWLOF MFC GJS

14
Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-09-19 globenewswire
TORONTO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Financial 15 Split Corp. ("Financial 15") declares its regular monthly distribution of $0.12570 for each Class A share ($1.51 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable October 10, 2018 to shareholders on record as at September 28, 2018.
CIFAF GLSSP GWO JBK TFG MFC 0945 CGBBW CIX SLFYF GWLIF SLF WFCNP SLF TD GS TD WFC TNTTF C GSC GSJ SLF GWLOF MFC GJS

10
Insurer Great-West Lifeco seeks to sell $2 bln worth of contracts- sources

2018-09-05 reuters
(Reuters) - Great-West Lifeco Inc (GWO.TO), Canada’s second-biggest insurance company, is exploring the sale of a collection of insurance contacts that could fetch as much as $2 billion, three people familiar with the matter said on Wednesday.
ATH GS GLSSP HIG GWO PWF HGH POFNF JBK GSC TFG GSJ GWLOF GJS GWLIF AGN

14
Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-08-20 globenewswire
TORONTO, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Financial 15 Split Corp. ("Financial 15") declares its regular monthly distribution of $0.12570 for each Class A share ($1.51 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable September 10, 2018 to shareholders on record as at August 31, 2018.
CIFAF GLSSP GWO JBK TFG MFC 0945 CGBBW CIX SLFYF GWLIF SLF WFCNP SLF TD GS TD WFC TNTTF C GSC GSJ SLF GWLOF MFC GJS

 
Big 8 Split Inc. Announces Quarterly Dividends on Class D Preferred Shares and Class D Capital Shares

2018-08-09 globenewswire
TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Big 8 Split Inc. (TSX:BIG.D) (TSX:BIG.pr.D) (the “Company”) announced today that it has declared a quarterly dividend of $0.1125 per Class D Preferred Share. In addition, a quarterly dividend on its Class D Capital Shares was declared of $0.043 per Class D Capital Share. The dividends on both the Class D Preferred Shares and Class D Capital Shares are payable on September 14, 2018 to holders of record on August 31, 2018.
SLF TD GWO TD TNTTF SLF MFC 0945 GWLOF MFC SLFYF GWLIF SLF

 
Great-West Lifeco, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-02 seekingalpha
The following slide deck was published by Great-West Lifeco, Inc. in conjunction with their 2018 Q2 earnings call.
GWLOF GWO GWLIF

14
North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-07-18 globenewswire
TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable August 10, 2018 to shareholders on record as at July 31, 2018.
CIFAF GLSSP GWO JBK TFG MFC 0945 CGBBW CIX SLFYF GWLIF SLF WFCNP FFN NAF.UN SLF TD GS TD WFC TNTTF C GSC GSJ SLF GWLOF MFC GJS

14
Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-07-18 globenewswire
TORONTO, July 18, 2018 (GLOBE NEWSWIRE) -- Financial 15 Split Corp. ("Financial 15") declares its regular monthly distribution of $0.12570 for each Class A share ($1.51 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable August 10, 2018 to shareholders on record as at July 31, 2018.
CIFAF GLSSP GWO JBK TFG MFC 0945 CGBBW CIX SLFYF GWLIF SLF WFCNP SLF TD GS TD WFC TNTTF C GSC GSJ SLF GWLOF MFC GJS

 
Trump Toronto hotel buyer sets sights on America

2018-07-06 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
CBG GWLOF GWO TCN GWLIF CBRE TCN.DB.A

5
E-L Financial - 38% Discount To A Growing Book Value With A Potential Catalyst

2018-06-25 seekingalpha
E-L Financial (OTCPK:ELFIF) is a holding company. It's a quiet, Canadian-style holding company, long owned by the Jackman family, who founded it. The management team is one of the least promotional I've ever seen; the company doesn't even have a website. Of course, it does file its financials with the Canadian equivalent of the SEC. Given those financials are in Canadian dollars and the company trades more volume in Canada under the symbol ELF, all figures in this report are in that currency unless otherwise noted.
UNC AGMJF EVT ECVTF GWLOF GWO ELF MFC GWLIF UCPLF ALC SLF

3
Attitudes to Brexit sour at the world’s biggest companies - Financial News

2018-06-25 fnlondon
Extensive analysis of the earnings calls of the world’s biggest companies shows the business community’s attitude to Brexit has soured significantly two years on from the UK’s vote to leave the European Union.
GWLOF GWO GWLIF

12
An Undervalued Large-Cap Financial Firm You Probably Have Never Heard Of

2018-05-18 seekingalpha
Canadian financial firm Power Corporation of Canada is a holding company with interesting and diverse assets.
BNPQY IGM BNPQF BNPZY GWLOF GWO PWF IGIFF GWLIF GRWTF POFNF

182
North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
CIFAF GLSSP GWO JBK TFG MFC 0945 CGBBW CIX SLFYF GWLIF SLF WFCNP FFN NAF.UN SLF TD GS TD WFC TNTTF C GSC GSJ SLF GWLOF MFC GJS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...